Belotecan
Clinical data | |
---|---|
ATC code | None |
Identifiers | |
| |
CAS Number | 256411-32-2 |
PubChem (CID) | 6456014 |
ChemSpider | 4958253 |
UNII | 27Z82M2G1N |
ChEMBL | CHEMBL2107315 |
Chemical and physical data | |
Formula | C25H27N3O4 |
Molar mass | 433.50 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Belotecan is a drug used in chemotherapy. It is a semi-synthetic camptothecin analogue indicated for Small Cell Lung Cancer and Ovarian Cancer, approved in South Korea under the trade name Camtobell(R), presented in 2 mg vials for injection.[1] The drug is marketed by ChongKunDang Pharmaceuticals [2] since 2003 [3]
Belotecan blocks topoisomerase I with a pIC50 of 6.56,[4] stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication.
References
- ↑ http://www.ckdpharm.com/eng/ckd/product/productView.ckd?seq=2463
- ↑ http://www.ckdpharm.com/eng/ckd/index.ckd
- ↑ Sahoo, Umakanta (2012). Clinical Research in Asia: Opportunities and Challenges. Oxford: Woodhead Publishing Limited. p. 152. ISBN 978-1-908818-13-3.
New drugs approved in South Korea
- ↑ "belotecan". drugcentral.org. UNM School of Medicine. 2016-07-31. Retrieved 2016-11-12.